跳至主要内容
临床试验/NCT00897910
NCT00897910终止不适用

Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC

Barbara Ann Karmanos Cancer Institute1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2008年4月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
6
试验地点
1
主要终点
Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry

研究概览

简要总结

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma.

PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.

详细描述

OBJECTIVES:

Primary

  • To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs) in peripheral blood and bone marrow samples from patients with multiple myeloma.

Secondary

  • To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3/CD28 stimulation.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry

时间窗: Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.

次要结局

  • Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation(Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zaid Al-Kadhimi

Principal Investigator

Barbara Ann Karmanos Cancer Institute

研究点 (1)

Loading locations...

相似试验

Studying T Cells in Blood and Bone Marrow Samples... | 临床试验